Squarepoint
AQST icon

Squarepoint’s Aquestive Therapeutics AQST Stock Holding History

Squarepoint’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$210K Sell
45,260
-25,162
-36% -$112K ﹤0.01% 4040
2026
Q2 		$293K Sell
70,422
-179,060
-72% -$754K ﹤0.01% 3818
2026
Q1 		$1.04M Buy
+249,482
New +$1.01M ﹤0.01% 2754
2025
Q3 		– Sell
-26,034
Closed -$86.2K – 4338
2025
Q2 		$86.2K Buy
+26,034
New +$74.7K ﹤0.01% 4205
2024
Q4 		– Sell
-85,392
Closed -$425K – 5001
2024
Q3 		$425K Buy
85,392
+51,991
+156% +$202K ﹤0.01% 3216
2024
Q2 		$86.8K Sell
33,401
-5,845
-15% -$19.5K ﹤0.01% 3821
2024
Q1 		$167K Buy
+39,246
New +$131K ﹤0.01% 3671
2023
Q4 		– Sell
-75,683
Closed -$116K – 3982
2023
Q3 		$116K Sell
75,683
-47,824
-39% -$82.2K ﹤0.01% 3541
2023
Q2 		$204K Buy
123,507
+107,965
+695% +$195K ﹤0.01% 3216
2023
Q1 		$17.7K Buy
+15,542
New +$13.5K ﹤0.01% 3138
2021
Q3 		– Sell
-19,824
Closed -$79K – 2881
2021
Q2 		$79K Buy
+19,824
New +$79.2K ﹤0.01% 3056
2021
Q1 		– Sell
-42,797
Closed -$229K – 3081
2020
Q4 		$229K Buy
+42,797
New +$256K ﹤0.01% 2415
2020
Q3 		– Sell
-193,856
Closed -$942K – 2473
2020
Q2 		$942K Buy
193,856
+177,431
+1,080% +$817K 0.02% 982
2020
Q1 		$36K Sell
16,425
-2,225
-12% -$8.45K ﹤0.01% 1742
2019
Q4 		$109K Sell
18,650
-22,127
-54% -$115K ﹤0.01% 2331
2019
Q3 		$130K Buy
40,777
+2,587
+7% +$9.7K ﹤0.01% 2155
2019
Q2 		$160K Buy
38,190
+22,190
+139% +$114K ﹤0.01% 2151
2019
Q1 		$111K Sell
16,000
-13,828
-46% -$96.9K ﹤0.01% 2026
2018
Q4 		$188K Buy
+29,828
New +$377K ﹤0.01% 1703

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $45.4M AUM 17.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $52.3B AUM 19.7% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Squarepoint's AQST Position: Q3 2026 in Review

Squarepoint reduced its Aquestive Therapeutics (AQST) stake by 36% in Q3 2026, selling an estimated $112K and leaving 45,260 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #4040.

Squarepoint first reported a position in AQST in Q4 2018 and has held it in 19 quarters since. The position peaked at $1.04M in Q1 2026. 110 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • Squarepoint held 45,260 shares of Aquestive Therapeutics worth $210K as of Q3 2026.
  • Squarepoint sold 25,162 Aquestive Therapeutics shares in Q3 2026, an estimated $112K.
  • Aquestive Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4040 holding.
  • Squarepoint first reported a position in Aquestive Therapeutics in Q4 2018 and has held it in 19 quarters since.
  • Squarepoint's Aquestive Therapeutics position peaked at $1.04M in Q1 2026.
  • 110 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.